import

One of the key barriers to improved access to Cannabis Based Products in the current framework is cost.  Sativex, available on-label for MS, has less than 12 people using it in NZ for that purpose, out of a patient population of 3000+ where trials demonstrate that a little over 40% of medium to severe patients gain sustained clinical benefit, there are hundreds of patients with this one condit...
Read More